Trésallet Christophe, Seman Marie, Tissier Frédérique, Buffet Camille, Lupinacci Renato Micelli, Vuarnesson Hélène, Leenhardt Laurence, Menegaux Fabrice
Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
Department of General, Digestive and Endocrine Surgery, Pierre-et-Marie Curie University (Paris VI), Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
Surgery. 2014 Nov;156(5):1145-52. doi: 10.1016/j.surg.2014.04.020. Epub 2014 May 27.
The connection between high body mass index (BMI), risk of papillary thyroid carcinoma (PTC), and the aggressiveness of PTC is still debated. We aimed to establish the relationship between excess BMI and the risk of PTC in an operative population, and the impact of obesity on histopathologic aggressiveness of PTC and on the outcome of patients.
All consecutive patients who underwent thyroid operation from June 2002 to December 2009 were reviewed in this retrospective study. BMI groupings were based on standardized categories: normal-weight, overweight, and obesity. We performed a total thyroidectomy with lymph node dissection in patients with preoperative or operative diagnosis of PTC. Radioiodine ablation was performed in every N1 patient, in case of tumor size greater than 10 mm, and if there was extrathyroidal invasion. During a median follow-up of 6.2 years, patients who were retreated by operation or (131)I were considered to have a persistent (<18 months of the initial operative treatment) or recurrent (≥ 18 months) disease.
Of 6,684 patients who had a thyroid gland resection, we identified 1,216 (18.2%) patients with PTC. Patients who were overweight or obese were not at greater risk of PTC than normal-weight subjects. Indications for operation or radioiodine therapy were similar in the three BMI groups. During follow-up, 86 patients (7.1%) experienced persistent (4.5%) or recurrent (2.5%) disease. When excluding micro-PTCs (≤ 10 mm), we found an association between recurrent or residual locoregional thyroid cancer and BMI: 18.7% in obese patients versus 8.5% if BMI <25 kg/m(2) and 9.8% if 25 ≥ BMI < 30 kg/m(2) (P = .03). This difference was clearly marked for persistence. When adjusted for other cofounder factors, we observed that BMI was an independent factor associated with the risk of postoperative locoregional event (odds ratio 3.8, 95% confidence interval 1.6-8.8), with sex, age, lymph node metastasis, and tumor bilaterality.
In macro-PTC, obese patients had an increased risk of developing a locoregional event during the follow-up, specifically a persistence of the disease. According to these results, overweight and obese patients with macro-PTC should be monitored more carefully for early detection of cancer persistence.
高体重指数(BMI)与甲状腺乳头状癌(PTC)风险及PTC侵袭性之间的关联仍存在争议。我们旨在确定手术人群中超重BMI与PTC风险之间的关系,以及肥胖对PTC组织病理学侵袭性和患者预后的影响。
本回顾性研究纳入了2002年6月至2009年12月期间所有连续接受甲状腺手术的患者。BMI分组基于标准类别:正常体重、超重和肥胖。对术前或术中诊断为PTC的患者行全甲状腺切除术及淋巴结清扫术。对于N1期患者,若肿瘤大小大于10mm且存在甲状腺外侵犯,则进行放射性碘消融。在中位随访6.2年期间,接受再次手术或(131)I治疗的患者被视为患有持续性(初始手术治疗后<18个月)或复发性(≥18个月)疾病。
在6684例接受甲状腺切除术的患者中,我们确定了1216例(18.2%)PTC患者。超重或肥胖患者患PTC的风险并不高于正常体重受试者。三个BMI组的手术或放射性碘治疗指征相似。随访期间,86例患者(7.1%)出现持续性(4.5%)或复发性(2.5%)疾病。排除微小PTC(≤10mm)后,我们发现复发性或残留局部甲状腺癌与BMI之间存在关联:肥胖患者为18.7%,而BMI<25kg/m²的患者为8.5%,25≤BMI<30kg/m²的患者为9.8%(P = 0.03)。这种差异在持续性方面尤为明显。在对其他混杂因素进行调整后,我们观察到BMI是与术后局部事件风险相关的独立因素(比值比3.8,95%置信区间1.6 - 8.8),与性别、年龄、淋巴结转移和肿瘤双侧性有关。
在大PTC中,肥胖患者在随访期间发生局部事件的风险增加,尤其是疾病的持续性。根据这些结果,超重和肥胖的大PTC患者应更密切地监测,以便早期发现癌症持续性。